BTIG Research upgraded shares of NeoGenomics (NASDAQ:NEO) from a neutral rating to an outperform rating in a report published on Monday morning.

A number of other equities analysts also recently weighed in on the stock. Canaccord Genuity boosted their target price on shares of NeoGenomics from $23.00 to $24.00 in a research note on Tuesday, March 13th. Royal Bank of Canada boosted their target price on shares of NeoGenomics from $23.00 to $24.00 and gave the stock an outperform rating in a research note on Tuesday, March 13th. Scotiabank boosted their target price on shares of NeoGenomics from $22.00 to $23.00 and gave the stock an outperform rating in a research note on Tuesday, March 13th. ValuEngine downgraded shares of NeoGenomics from a hold rating to a sell rating in a research note on Wednesday, March 7th. Finally, Zacks Investment Research raised shares of NeoGenomics from a sell rating to a hold rating in a research note on Thursday, March 1st. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $17.29.

How to Become a New Pot Stock Millionaire

NASDAQ:NEO opened at $9.05 on Monday. The stock has a market capitalization of $683.51, a price-to-earnings ratio of 150.83, a PEG ratio of 4.72 and a beta of 0.42. NeoGenomics has a 12 month low of $7.08 and a 12 month high of $11.63. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 0.56.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Wednesday, February 21st. The medical research company reported $0.04 EPS for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.02. The firm had revenue of $67.79 million for the quarter, compared to analyst estimates of $66.32 million. NeoGenomics had a negative net margin of 1.37% and a positive return on equity of 4.34%. The company’s revenue for the quarter was up 12.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.05 earnings per share. research analysts predict that NeoGenomics will post 0.09 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of NEO. Teacher Retirement System of Texas bought a new stake in shares of NeoGenomics during the fourth quarter worth approximately $182,000. Howland Capital Management LLC grew its holdings in NeoGenomics by 67.6% during the fourth quarter. Howland Capital Management LLC now owns 21,782 shares of the medical research company’s stock valued at $193,000 after purchasing an additional 8,782 shares during the period. MetLife Investment Advisors LLC acquired a new position in NeoGenomics during the fourth quarter valued at approximately $235,000. Aperio Group LLC acquired a new position in NeoGenomics during the fourth quarter valued at approximately $243,000. Finally, Stone Ridge Asset Management LLC acquired a new position in NeoGenomics during the fourth quarter valued at approximately $281,000. 84.63% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “NeoGenomics (NEO) Upgraded by BTIG Research to “Outperform”” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/04/17/neogenomics-neo-upgraded-by-btig-research-to-outperform.html.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.